"If one of your parents has had a broken bone, especially a broken hip, you may need to be screened earlier for osteoporosis. This is a medical condition where bones become weak and are more likely to break. Share your family health history with y"...
Binosto Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Binosto (alendronate sodium) is a bisphosphonate used in the treatment of osteoporosis in postmenopausal women, and in treatment to increase bone mass in men with osteoporosis. Common side effects of Binosto include:
- abdominal or stomach pain
- acid reflux
- musculoskeletal pain
- joint pain or swelling
- changes in taste
- abdominal bloating
- muscle cramps
- eye pain, or
- swelling in your hands or feet
Binosto is available as a 70 mg effervescent tablet. Binosto is contraindicated for patients with abnormalities of the esophagus which delay emptying such as stricture or achalasia (difficulty swallowing) ,and for patients with hypersensitivity to any component of this product. Binosto may interact with other drugs. Tell your doctor all prescription and OTC medications you are taking. Binosto should be used during pregnancy only if the potential benefit justifies the potential risk to the mother and fetus. It is not known whether alendronate is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Binosto is administered to nursing women.
Binosto (alendronate sodium) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Binosto FDA Prescribing Information: Side Effects
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety of BINOSTO (alendronate sodium) effervescent tablet 70 mg is based on clinical trial data of alendronate sodium 10 mg daily and alendronate sodium 70 mg weekly.
Treatment of Osteoporosis in Postmenopausal Women
The safety of alendronate sodium 10 mg daily in the treatment of postmenopausal osteoporosis was assessed in four clinical trials that enrolled 7453 women aged 44-84 years. Study 1 and Study 2 were identically designed, three-year, placebo-controlled, double-blind, multicenter studies (United States and Multinational n=994); Study 3 was the three year vertebral fracture cohort of the Fracture Intervention Trial [FIT] (n=2027) and Study 4 was the four-year clinical fracture cohort of FIT (n=4432). Overall, 3620 patients were exposed to placebo and 3432 patients exposed to alendronate. Patients with pre-existing gastrointestinal disease and concomitant use of non-steroidal anti-inflammatory drugs were included in these clinical trials. In Study 1 and Study 2 all women received 500 mg elemental calcium as carbonate. In Study 3 and Study 4 all women with dietary calcium intake less than 1000 mg per day received 500 mg calcium and 250 IU Vitamin D per day.
Among patients treated with alendronate 10 mg or placebo in Study 1 and Study 2, and all patients in Study 3 and Study 4, the incidence of all-cause mortality was 1.8% in the placebo group and 1.8% in the alendronate group. The incidence of serious adverse events was 30.7% in the placebo group and 30.9% in the alendronate group. The percentage of patients who discontinued the study due to any clinical adverse event was 9.5% in the placebo group and 8.9% in the alendronate group. Adverse reactions from these studies considered by the investigators as possibly, probably, or definitely drug related in greater than or equal to 1% of patients treated with either alendronate or placebo are presented in Table 1.
Table 1 : Osteoporosis Treatment Studies in
Postmenopausal Women Adverse Reactions Considered Possibly, Probably, or
Definitely Drug Related by theInvestigators and Reported in Greater Than or
Equal to 1% of Patients
|United States/ Multinational Studies||Fracture Intervention Trial|
|Alendronate Sodium* %
|Alendronate Sodium** %
|Musculoskeletal (bone, muscle or joint) pain||4.1||2.5||0.4||0.3|
|* 10 mg/day for three years
** 5 mg/day for 2 years and 10 mg/day for either 1 or 2 additional years
Rarely, rash and erythema have occurred.
Gastrointestinal Adverse Reactions: One patient treated with alendronate sodium (10 mg/day), who had a history of peptic ulcer disease and gastrectomy and who was taking concomitant aspirin developed an anastomotic ulcer with mild hemorrhage, which was considered drug related. Aspirin and alendronate sodium were discontinued and the patient recovered. In the Study 1 and Study 2 populations, 49-54% had a history of gastrointestinal disorders at baseline and 54-89% used nonsteroidal anti-inflammatory drugs or aspirin at some time during the studies [see WARNINGS AND PRECAUTIONS].
Laboratory Test Findings: In double-blind, multicenter, controlled studies, asymptomatic, mild, and transient decreases in serum calcium and phosphate were observed in approximately 18% and 10%, respectively, of patients taking alendronate versus approximately 12% and 3% of those taking placebo. However, the incidences of decreases in serum calcium to less than 8.0 mg/dL (2.0 mM) and serum phosphate to less than or equal to 2.0 mg/dL (0.65 mM) were similar in both treatment groups.
The safety of alendronate sodium 70 mg once weekly for the treatment of postmenopausal osteoporosis was assessed in a one-year, double-blind, multicenter study comparing alendronate 70 mg once weekly and alendronate 10 mg daily. The overall safety and tolerability profiles of once weekly alendronate 70 mg and alendronate 10 mg daily were similar. The adverse reactions considered by the investigators as possibly, probably, or definitely drug related in greater than or equal to 1% of patients in either treatment group are presented in Table 2.
Table 2 : Osteoporosis
Treatment Studies in Postmenopausal Women Adverse Reactions Considered Possibly,
Probably, or Definitely Drug Related by theInvestigators and Reported in
Greater Than or Equal to 1% of Patients
|Once Weekly Alendronate Sodium 70 mg %
|Once Daily Alendronate Sodium 10 mg %
|Musculoskeletal (bone, muscle, joint) pain||2.9||3.2|
Osteoporosis in Men
In two placebo-controlled, double-blind, multicenter studies in men (a two-year study of alendronate sodium 10 mg/day and a one-year study of once weekly alendronate sodium 70 mg) the rates of discontinuation of therapy due to any clinical adverse event were 2.7% for alendronate 10 mg/day vs. 10.5% for placebo, and 6.4% for once weekly alendronate 70 mg vs. 8.6% for placebo. The adverse reactions considered by the investigators as possibly, probably, or definitely drug related in greater than or equal to 2% of patients treated with either alendronate or placebo are presented in the following table.
Table 3 : Osteoporosis Studies in Men Adverse Reactions Considered Possibly, Probably, or
Definitely Drug Related by the Investigators
and Reported in Greater Than or Equal to 2% of Patients
|Two-Year Study||One-Year Study|
|Once Daily Alendronate Sodium 10 mg %
|Once Weekly Alendronate Sodium 70 mg %
|Gastroesophageal reflux disease||0.7||3.2||2.8||0.0|
The following adverse reactions have been identified during post-approval use of alendronate sodium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Body as a Whole: hypersensitivity reactions including urticaria and angioedema. Transient symptoms of myalgia, malaise, asthenia and fever have been reported with alendronate, typically in association with initiation of treatment. Symptomatic hypocalcemia has occurred, generally in association with predisposing conditions. Peripheral edema.
Gastrointestinal: esophagitis, esophageal erosions, esophageal ulcers, esophageal stricture or perforation, and oropharyngeal ulceration. Gastric or duodenal ulcers, some severe and with complications have also been reported [see DOSAGE AND ADMINISTRATION; WARNINGS AND PRECAUTIONS].
Musculoskeletal: bone, joint, and/or muscle pain, occasionally severe and incapacitating [see WARNINGS AND PRECAUTIONS]; joint swelling; low-energy femoral shaft and subtrochanteric fractures [see WARNINGS AND PRECAUTIONS].
Nervous system: dizziness and vertigo.
Pulmonary: asthma exacerbations
Read the entire FDA prescribing information for Binosto (Alendronate Sodium Effervescent Tablets)
Additional Binosto Information
- Binosto Drug Interactions Center: alendronate oral
- Binosto Side Effects Center
- Binosto FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips and advances in treatment.